Dr Timothy Wright – AfricaNewsAnalysis

New data show Novartis’ Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients

07/10/2013 ANA 0

Novartis recently announced new data indicating that continued treatment with Gilenya® (fingolimod) led to a reduction in brain volume loss in patients with relapsing forms of multiple sclerosis (MS), and was associated with a higher […]

Novartis announces positive results from final Phase III omalizumab registration study in severe form of chronic skin disease CSU

05/10/2013 ANA 0

Novartis announced today new results from the Phase III ASTERIA I study showing omalizumab was effective and safe in the treatment of chronic spontaneous urticaria (CSU)[1], a chronic and debilitating form of hives. ASTERIA I […]

New data for Novartis drug Lucentis® reinforces transformational efficacy and well-established safety profile across four indications

01/10/2013 ANA 0

New clinical and real world data for Lucentis® (ranibizumab) presented in over 40 abstracts at this week’s EURETINA congress confirm its transformational and well-established safety profile in four retinal diseases. Designed for intraocular use, Lucentis […]

Novartis showcases 39 abstracts highlighting robust respiratory portfolio at ERS 2013

05/09/2013 ANA 0

New data to be presented from the Novartis respiratory portfolio at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, Spain, further demonstrates Novartis’ commitment to providing treatment options for patients with chronic obstructive […]

Novartis receives EU approval for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis

03/09/2013 ANA 0

Novartis announced today that the European Commission (EC) has approved the use of Ilaris® (canakinumab) in the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older, who have responded […]

Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis

10/06/2013 ANA 0

Two new analyses from the Phase III TRANSFORMS study presented at the 23rd meeting of the European Neurological Society (ENS) in Barcelona, demonstrated how Novartis’ Gilenya® (fingolimod) was effective against all four key measures of […]